These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23972562)

  • 1. The applause sign in Parkinson's disease patients is related to dysexecutive syndrome.
    Tomic S; Vladetic M; Solic K; Misevic S; Soldo SB
    J Clin Neurosci; 2013 Dec; 20(12):1734-6. PubMed ID: 23972562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The applause sign and neuropsychological profile in progressive supranuclear palsy and Parkinson's disease.
    Somme J; Gómez-Esteban JC; Tijero B; Berganzo K; Lezcano E; Zarranz JJ
    Clin Neurol Neurosurg; 2013 Aug; 115(8):1230-3. PubMed ID: 23253819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applause sign in advanced Parkinson's disease.
    Weerkamp NJ; Tissingh G; Poels PJ; Zuidema SU; Munneke M; Koopmans RT; Bloem BR
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1268-9. PubMed ID: 25260968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memory and executive function impairment predict dementia in Parkinson's disease.
    Levy G; Jacobs DM; Tang MX; Côté LJ; Louis ED; Alfaro B; Mejia H; Stern Y; Marder K
    Mov Disord; 2002 Nov; 17(6):1221-6. PubMed ID: 12465060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between cognitive dysfunction and behavioural symptoms in Nigerian patients with Parkinson's disease no dementia.
    Ojagbemi A
    J Parkinsons Dis; 2013 Jan; 3(3):293-300. PubMed ID: 23963316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of the "applause sign" in patients with amyotrophic lateral sclerosis.
    Anneser JM; Krzovska M; Borasio GD; Danek A
    Clin Neurol Neurosurg; 2015 Oct; 137():8-10. PubMed ID: 26117556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applause sign: screening utility for dementia and cognitive impairment.
    Bonello M; Larner AJ
    Postgrad Med; 2016; 128(2):250-3. PubMed ID: 26560747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Executive dysfunction using behavioral assessment of the dysexecutive syndrome in Parkinson's disease.
    Kamei S; Hara M; Serizawa K; Murakami M; Mizutani T; Ishiburo M; Kawahara R; Takagi Y; Ogawa K; Yoshihashi H; Shinbo S; Suzuki Y; Yamaguchi M; Morita A; Takeshita J; Hirayanagi K
    Mov Disord; 2008 Mar; 23(4):566-73. PubMed ID: 18098279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioural assessment of dysexecutive syndrome in Parkinson's disease without dementia: a comparison with other clinical executive tasks.
    Perfetti B; Varanese S; Mercuri P; Mancino E; Saggino A; Onofrj M
    Parkinsonism Relat Disord; 2010 Jan; 16(1):46-50. PubMed ID: 19665420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CERAD test performance and cognitive impairment in Parkinson's disease.
    Karrasch M; Laatu S; Martikainen K; Marttila R
    Acta Neurol Scand; 2013 Dec; 128(6):409-13. PubMed ID: 23668316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cognition deterioration in Parkinson's disease: associated risk factors].
    Errea JM; Ara JR
    Rev Neurol; 1999 Mar 1-15; 28(5):439-43. PubMed ID: 10229953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The applause sign in cortical and cortical-subcortical dementia.
    Isella V; Rucci F; Traficante D; Mapelli C; Ferri F; Appollonio IM
    J Neurol; 2013 Apr; 260(4):1099-103. PubMed ID: 23212756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The independent influence of apathy and depression on cognitive functioning in Parkinson's disease.
    Butterfield LC; Cimino CR; Oelke LE; Hauser RA; Sanchez-Ramos J
    Neuropsychology; 2010 Nov; 24(6):721-30. PubMed ID: 20853956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
    Hanagasi HA; Gurvit H; Unsalan P; Horozoglu H; Tuncer N; Feyzioglu A; Gunal DI; Yener GG; Cakmur R; Sahin HA; Emre M
    Mov Disord; 2011 Aug; 26(10):1851-8. PubMed ID: 21500280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing an aetiological model of visual hallucinations in Parkinson's disease.
    Gallagher DA; Parkkinen L; O'Sullivan SS; Spratt A; Shah A; Davey CC; Bremner FD; Revesz T; Williams DR; Lees AJ; Schrag A
    Brain; 2011 Nov; 134(Pt 11):3299-309. PubMed ID: 21921019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease.
    Llebaria G; Pagonabarraga J; Kulisevsky J; García-Sánchez C; Pascual-Sedano B; Gironell A; Martínez-Corral M
    Mov Disord; 2008 Aug; 23(11):1546-50. PubMed ID: 18546326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Odor identification deficits identify Parkinson's disease patients with poor cognitive performance.
    Damholdt MF; Borghammer P; Larsen L; Ostergaard K
    Mov Disord; 2011 Sep; 26(11):2045-50. PubMed ID: 21638326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson's disease.
    Brown GG; Rahill AA; Gorell JM; McDonald C; Brown SJ; Sillanpaa M; Shults C
    J Geriatr Psychiatry Neurol; 1999; 12(4):180-8. PubMed ID: 10616865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between extrapyramidal signs and cognitive function in a community-dwelling cohort of patients with Parkinson's disease and normal elderly individuals.
    Richards M; Stern Y; Marder K; Cote L; Mayeux R
    Ann Neurol; 1993 Mar; 33(3):267-74. PubMed ID: 8498810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive impairments in Parkinson's disease.
    Levin BE; Tomer R; Rey GJ
    Neurol Clin; 1992 May; 10(2):471-85. PubMed ID: 1584185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.